Hsu T.-C.CHI-CHUAN WANG2021-07-052021-07-052019204263052-s2.0-85059096340https://scholars.lib.ntu.edu.tw/handle/123456789/568957Aim: Oral uracil-tegafur/leucovorin (UFT/LV) and intravenous 5-fluorouracil (FU)/LV are common adjuvant therapies for Stages II and III colorectal cancer. This study aims to determine the most cost-effective treatment alternative between UFT/LV and 5-FU/LV in Stages II and III colorectal cancer from Taiwan's National Health Insurance perspective. Patients & methods: The costs were referenced directly from the National Health Insurance reimbursement price. Chemotherapy regimen considered for the cost analysis calculation was adapted from NSABP-C-06 study, and, a time saving calculation was also included. In addition, we compare the treatment outcome. Result: A total cost saving of US$3620.80-$3709.16 per patient per treatment was achieved with the UFT/LV treatment. UFT/LV provides the comparable outcome to 5-FU/LV. Conclusion: UFT/LV was the more cost-effective treatment as adjuvant chemotherapy. ? 2019 2018 Future Medicine Ltd.chemotherapy; cost-effective; NHI reimbursement price; oral; stage II and III colorectal cancer; UFT; uracil-tegafur[SDGs]SDG3fluorouracil; folinic acid; UFT; ufur; antineoplastic agent; antineoplastic antimetabolite; fluorouracil; folinic acid; tegafur; uracil; vitamin B complex; Article; cancer chemotherapy; cancer staging; clinical article; colorectal cancer; controlled study; cost benefit analysis; cost control; cost effectiveness analysis; disease free survival; drug cost; hospital admission; human; multiple cycle treatment; overall survival; priority journal; Taiwan; treatment outcome; adjuvant chemotherapy; adult; aged; colorectal tumor; economics; female; health care cost; male; middle aged; multimodality cancer therapy; oral drug administration; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Combined Modality Therapy; Cost Control; Female; Fluorouracil; Health Care Costs; Humans; Leucovorin; Male; Middle Aged; Taiwan; Tegafur; Treatment Outcome; Uracil; Vitamin B Complexjournal article10.2217/cer-2018-007830560687